<DOC>
	<DOCNO>NCT00571259</DOCNO>
	<brief_summary>The study randomize , double blind , prospective , multicenter , clinical trial . All patient require vascular access tunnel central venous catheter hemodialysis eligible enrollment . Patients randomize receive either Heparin 1,000 U/ml volume sufficient fill catheter length port receive 4 % Sodium Citrate Gentamicin 320 mcg/mL volume sufficient fill catheter length ports.We hypothesize device relate infection rate Citrate/Gentamicin group less heparin arm .</brief_summary>
	<brief_title>Prophylactic Antimicrobial Catheter Lock</brief_title>
	<detailed_description />
	<mesh_term>Bacteremia</mesh_term>
	<mesh_term>Gentamicins</mesh_term>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Requires placement central venous catheter currently central venous catheter hemodialysis access . Must least 18 year old Compliant dialysis treatment schedule Plans continue hemodialysis treatment followup investigational site Must able care exit site independently someone able care site Must able sign inform consent document The subject infection associate one positive blood culture eligible 14 day blood culture become negative clinical resolution episode occur Active exit site tunnel infection Systemic localize infection unresponsive antibiotic therapy and/or life threaten Known antibody heparin Allergy pork heparin Allergy gentamicin Subject pregnant Known intravenous drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Sodium citrate</keyword>
	<keyword>Gentamicin</keyword>
	<keyword>Prophylaxis</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>Central venous catheter</keyword>
</DOC>